Valeant Pharmaceuticals adds prominent United States investor John Paulson to board
- Author: Zachary Reyes Jun 21, 2017,
Jun 21, 2017, 23:06
The institutional investor bought 1,017,557 shares of the specialty pharmaceutical company's stock, valued at approximately $11,223,000. Harbor Advisors LLC acquired a new stake in shares of Valeant Pharmaceuticals International during the first quarter valued at about $110,000. The Shareholder Yield (Mebane Faber) of Valeant Pharmaceuticals International, Inc.
The stock has actually made sharp losses in the past year, as the company has gathered a -41.61% return in the past twelve months. It has underperformed by 65.21% the S&P500. The company have shares float of 337.69 million. Consequently, the shares traded in green and surged as much as 6.40% during active trading yesterday. Hasbro Inc Com now has $13.94B valuation. The stock declined 1.48% or $0.2 reaching $13.27 on the news. LeJeune Puetz Investment Counsel LLC acquired a new stake in shares of Valeant Pharmaceuticals International during the fourth quarter valued at about $123,000. Applied Matls Inc (NASDAQ:AMAT) was reduced too.
Analysts await Hasbro, Inc. Envestnet Asset Inc reported 0% in Gigamon Inc (NYSE:GIMO). They expect $0.46 earnings per share, up 12.20% or $0.05 from last year's $0.41 per share.
As stocks has a P/S, P/E and P/B estimations of 0.49, n/a and 1.18 separately. 14 issued rating as a HOLD.3 said as SELL recommendations and 1 suggested UNDERWEIGHT rating. AmerisourceBergen had 36 analyst reports since July 27, 2015 according to SRatingsIntel. Jefferies maintained Hasbro, Inc. The company was initiated on Tuesday, April 11 by Guggenheim.
A few investment analysts have released opinions on the stock. The stock has "Outperform" rating by Macquarie Research on Monday, November 30. The rating was initiated by BMO Capital Markets with "Market Perform" on Wednesday, June 29. Morgan Stanley downgraded the stock and lowered the price target on December 15 changing the price objective from $23.00 to $17.00 and moving the rating from "Neutral" to "Equal-Weight". HC Wainwright set a $23.00 target price on Valeant Pharmaceuticals International and gave the stock a "hold" rating in a research note on Tuesday, February 28th. JP Morgan maintained Hasbro, Inc. Zacks upgraded Anika Therapeutics Inc (NASDAQ:ANIK) rating on Wednesday, August 26. Credit Suisse has "Outperform" rating and $121 target.
Investors sentiment increased to 1.12 in Q4 2016. Its down 0.01, from 0.9 in 2016Q3. Accipiter Ltd Co holds 14.03% or 1.21 million shares. First Personal Fincl Services holds 0% or 133 shares. Tudor Et Al accumulated 0.03% or 17,367 shares. (NASDAQ:HAS) for 24,744 shares. Alps Advsrs reported 0% in Anika Therapeutics Inc (NASDAQ:ANIK). Bnp Paribas Arbitrage stated it has 1.04 million shares. Kazazian Asset Mgmt Limited Liability Com holds 0.71% or 35,165 shares. (NASDAQ:HAS) for 200 shares. Banque Pictet And Cie Sa holds 39,628 shares.
Investors sentiment decreased to 0.78 in 2016 Q4. Its up 0.30, from 0.59 in 2016Q3.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. 20 funds opened positions while 51 raised stakes. Invesco reported 42,535 shares. Twin Tree Ltd Partnership reported 5,100 shares.
Valeant Pharmaceuticals International, Inc. has a 52-week low of $8.31 and a 52-week high of $32.74. On the other side, analysts now consider Valeant Pharmaceuticals International, Inc. a sell, and a technical analysis of the stock is setting somewhat neutral outlook for now. Prudential Public Limited has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Prior to that, he held roles of increasing importance in investor relations at Thomson Financial and Dynegy, Inc. 104,840 are owned by Two Sigma Ltd Liability Corporation. 5 are held by Synovus Fincl Corporation. Cubist Systematic Strategies Lc, Connecticut-based fund reported 12,614 shares. Columbus Hill Capital Mngmt LP owns 685,000 shares or 1.12% of their United States portfolio. Winfield Incorporated owns 90 shares.
Out of the 16 analysts polled by TipRanks (in the past 12 months), 3 rate Valeant stock a Buy, 10 rate the stock a Hold and 3 recommend to Sell. Therefore 24% are positive.
Great West Life Assurance Company decreased Valeant Pharmaceuticals Intl (VRX) stake by 55.74% reported in 2016Q4 SEC filing. The company was initiated on Friday, October 9 by Mizuho.
Shares of Valeant Pharmaceuticals International (VRX) traded up 4.64% during mid-day trading on Tuesday, hitting $13.76. The stock has "Buy" rating by Bank of America on Wednesday, September 30. The firm has "Buy" rating given on Wednesday, November 11 by Stifel Nicolaus. The current share price indicate that stock is -10.89% away from its one year high and is moving 25.64% ahead of its 52-week low. The firm has "Buy" rating given on Monday, October 31 by Goldman Sachs.